Relevant bibliographies by topics / CESAR Central European Society for Anticancer Drug Research

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Conference papers

Academic literature on the topic 'CESAR Central European Society for Anticancer Drug Research'

Author: Grafiati
Published: 4 June 2021
Last updated: 28 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'CESAR Central European Society for Anticancer Drug Research.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "CESAR Central European Society for Anticancer Drug Research"

1

Dittrich, C., and B. Keppler. "Central European Society for Anticancer Drug Research (CESAR)." Oncology Research and Treatment 23, no. 5 (2000): 492–93. http://dx.doi.org/10.1159/000027220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dittrich, C., M. Gneist, A. Zandvliet, C. Johnston, and M. Yule. "431 Phase I and pharmacokinetic study of indisulam (E7070) in combination with carboplatin, a CESAR Central European Society for Anticancer Drug Research — EWIV report." European Journal of Cancer Supplements 2, no. 8 (2004): 129. http://dx.doi.org/10.1016/s1359-6349(04)80439-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hartung, G. "Annual Meeting of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research – EWIV (CESAR)." Int. Journal of Clinical Pharmacology and Therapeutics 42, no. 11 (2004): 631. http://dx.doi.org/10.5414/cpp42631.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Steinbild, S., K. Mross, D. Morant, et al. "Phase II study of Sorafenib (BAY 43–9006) in hormone-refractory patients with prostate cancer: A study of the Central European Society for Anticancer Drug Research—EWIV (CESAR)." Journal of Clinical Oncology 24, no. 18_suppl (2006): 3094. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.3094.

Full text
Abstract:
3094 Background: Sorafenib (BAY 43–9006) is a novel, orally active multi-kinase inhibitor with anti-angiogenic and anti-proliferative activity, blocking both Raf/MEK/ERK pathway and receptor tyrosine kinases VEGFR-2 and PDGFR. Activity of sorafenib in hormone-refractory progressive patients (pts) with prostate cancer (PC) was investigated in a Phase II clinical study. Methods: Pts received sorafenib 400 mg bid by continuous oral dosing. Pts with progressive disease during hormonal treatment and no prior chemotherapy therapy for advanced prostate cancer, and either one uni-dimensional measurabl
APA, Harvard, Vancouver, ISO, and other styles
5

Richly, Heike, Luise Maute, Gerhard Heil, et al. "Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV." Journal of Clinical Oncology 31, no. 15_suppl (2013): 4035. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4035.

Full text
Abstract:
4035 Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumours, but PDAC is still associated with a poor prognosis in advanced disease with an overall 5-year survival of only about 15%. Therefore there is a need for new treatment strategies. To improve the standard therapy with gemcitabine we initiated a prospective randomized phase-II trial with gemcitabine (GEM) vs. gemcitabine plus sunitinib (SUNGEM) based on data of in vitro trials and phase-I data for the combination treatment. Methods: Patients (N=113) with locally advanced or metastatic PDAC were pr
APA, Harvard, Vancouver, ISO, and other styles
6

Steinbild, S., K. Mross, A. Frost, et al. "A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV." British Journal of Cancer 97, no. 11 (2007): 1480–85. http://dx.doi.org/10.1038/sj.bjc.6604064.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hofheinz, R. D., C. Porta, G. Hartung, et al. "BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)." Investigational New Drugs 23, no. 4 (2005): 363–68. http://dx.doi.org/10.1007/s10637-005-1445-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Keppler, B. K. "Annual Meeting of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research (CESAR) during the Symposium ?Novel Approaches for the Discover." Int. Journal of Clinical Pharmacology and Therapeutics 43, no. 12 (2005): 566. http://dx.doi.org/10.5414/cpp43566.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hofheinz, R. D., C. Dittrich, M. A. Jakupec, et al. "Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors ? a CESAR study (Central European Society for Anticancer Drug Research ? EW." Int. Journal of Clinical Pharmacology and Therapeutics 43, no. 12 (2005): 590–91. http://dx.doi.org/10.5414/cpp43590.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dittrich, C., A. Hochhaus, S. Schaad, et al. "Phase I and pharmacokinetic study of the oral tris-(8-quinolinolato)gallium(III) complex (FFC11, KP46) in patients with solid tumors - a study of the CESAR Central European Society for Anticancer Drug Research - EWIV." Journal of Clinical Oncology 23, no. 16_suppl (2005): 3205. http://dx.doi.org/10.1200/jco.2005.23.16_suppl.3205.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "CESAR Central European Society for Anticancer Drug Research"

1

Miller, Kurt, Rudolf Morant, Arnulf Stenzl, Manfred P. Wirth, and Ivan Zuna. "A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium." Karger, 2016. https://tud.qucosa.de/id/qucosa%3A70589.

Full text
Abstract:
Introduction: This phase II trial evaluated the efficacy and safety of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, in combination with first-line chemotherapy in advanced urothelial cancer. Methods: Chemotherapy-naïve patients with advanced or metastatic urothelial carcinoma were randomized 1:1:1 to receive six cycles of chemotherapy (gemcitabine 1,250 mg/m 2 on days 1 and 8, and cisplatin 70 mg/m 2 on day 1 of every cycle) concomitantly with gefitinib 250 mg/day (arm A); or with sequential gefitinib (arm B); or alone (arm C). The primary endpoint was the
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "CESAR Central European Society for Anticancer Drug Research"

1

Gastl, G. Standard operating procedures for clinical trials of the CESAR Central European Society for Anticancer Drug Research - EWIV. Karger, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gastl, G. Ed. Standard Operating Procedures for Clinical Trials of the Central European Society for Anticancer Drug Research (Cesar-Ewiv (Supplement Issue: Onkologie 2003, 6). Not Avail, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "CESAR Central European Society for Anticancer Drug Research"

1

Hilger, Ralf Axel, Tobias Wegener, Heike Richly, Georg Ludwig, Klaus Mross, and Max E. Scheulen. "Abstract 1293: A phase I dose-escalation study with pharmacokinetics (PK) of TriN 2755 in patients with advanced solid tumors: A study in cooperation with the Central European Society for Anticancer Drug Research (CESAR-EWIV)." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-1293.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'CESAR Central European Society for Anticancer Drug Research' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography